Severe asthma concomitant with allergic bronchopulmonary aspergillosis (ABPA) and non-steroid exacerbated respiratory disease (N-ERD) successfully treated with mepolizumab: A case report

Mehmet Erdem ÇAKMAK (ID)
Clinic of Allergy and Clinical Immunology, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey
Başakşehir Çam ve Sakura Şehir Hastanesi, İmmünoloji ve Alerji Hastalıkları Kliniği, İstanbul, Türkiye

ABSTRACT
Severe asthma concomitant with allergic bronchopulmonary aspergillosis (ABPA) and non-steroid exacerbated respiratory disease (N-ERD) successfully treated with mepolizumab: A case report

Allergic bronchopulmonary aspergillosis (ABPA) is a lung disease characterized by a hypersensitivity reaction to Aspergillus fumigatus. Allergic bronchopulmonary aspergillosis is characterized by increased serum IgE levels, peripheral blood eosinophilia and radiographic pulmonary infiltrates, central bronchiectasis, and mucus plugs. Mepolizumab, a monoclonal interleukin (IL)-5 antibody, reduces eosinophilic inflammation and improves symptom control in severe eosinophilic asthma. A 74-year-old male patient arrived at our allergy outpatient clinic complaining of shortness of breath and cough. He had a history of asthma, NSAIDs Exacerbated Respiratory Disease (N-ERD) and endoscopic sinus surgery (ESS) due to chronic sinusitis with nasal polyps (CRSwNPs). At the time of admission to our clinic, his asthma control test (ACT) score was 5. The laboratory test results= eosinophil count (cells/mcL)= 570, total IgE= 3976 IU/mL, Aspergillus-specific IgE= 1.87 kIU/L (>0.35 positive). In the pulmonary function tests, forced expiratory volume in 1s (FEV₁) was 28%. Thoracic computed tomography of the patient revealed central cystic bronchiectatic areas and mucus plugs. The patient was diagnosed with ABPA. The case reported here is of a patient diagnosed with severe asthma concomitant with ABPA and N-ERD, who was successfully treated with mepolizumab. Randomized double-blind placebo-controlled studies are needed to evaluate the efficacy of mepolizumab treatment in these patients.

Key words: Allergic bronchopulmonary aspergillosis; mepolizumab; drug allergy; asthma; eosinophil
A case of severe asthma concomitant with ABPA and NERD successfully treated with mepolizumab

INTRODUCTION

Allergic bronchopulmonary aspergillosis (ABPA) is a lung disease characterized by a hypersensitivity reaction to Aspergillus fumigatus. Allergic bronchopulmonary aspergillosis is characterized by increased serum IgE levels, peripheral blood eosinophilia and radiographic pulmonary infiltrates, central bronchiectasis, and mucus plugs. In chronic cases, recurrent episodes of bronchial obstruction, inflammation, and mucoid impaction can lead to bronchiectasis, fibrosis, and respiratory failure. Systemic corticosteroids and antifungal agents are important in treating the disease and controlling its progression (1).

In a group of patients with asthma/rhinitis/nasal polyps as an underlying disease, it has been shown that exposure to aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs) causes respiratory complaints such as runny nose, sneezing, nasal congestion, cough, shortness of breath, and severe bronchospasm. This disease, which used to be called Samter’s syndrome, is now called “Non-steroidal Anti-Inflammatory Drug (NSAID) Exacerbated Respiratory Disease” (NSAID-Exacerbated Respiratory Disease: N-ERD). Most of these patients have severe eosinophilic asthma, and patients with N-ERD have a higher rate of severe asthma than other asthmatic patients (2).

Mepolizumab, a monoclonal interleukin (IL)-5 antibody, reduces eosinophilic inflammation and improves symptom control in severe eosinophilic asthma (3). The case reported here is of a patient diagnosed with severe asthma concomitant with ABPA and N-ERD, who was successfully treated with mepolizumab.

CASE REPORT

A 74-year-old male patient was admitted to our allergy outpatient clinic with complaints of shortness of breath and cough. He had a history of asthma for 40 years, diabetes and hypertension for 15 years, N-ERD (culprit drugs: aspirin, diclofenac, and ibuprofen) for 20 years, and endoscopic sinus surgery (ESS) 20 years ago due to chronic sinusitis with nasal polyps (CRSwNPs). The physical examination of the respiratory system revealed rhonchi in both lung fields. Saturation was 94% without supplemental nasal oxygen. Other physical examination findings were normal. The patient had been using salmeterol fluticasone 50/500 mcg 2 x 1/day, montelukast 10 mg/day, levocetirizine 5 mg/day, and intranasal mometasone 2 x 2 puffs/day. The patient’s inhaler technique and treatment compliance were good. At the time of admission to our clinic, his asthma control test (ACT) (4) score was 5. The laboratory tests showed eosinophil count (cells/ml) = 570, total IgE = 3976 IU/mL, Aspergillus-specific IgE = 1.87 kIU/L (>0.35 positive), Dermatophagoides pteronyssinus-specific IgE = 2.08 kIU/L (>0.35 positive), other aeroallergen-specific IgE <0.35 kIU/L (negative), sedimentation = 2 mm/h, and negativity of serum proteinase-3 anti-neutrophil cytoplasmic antibody (ANCA) and myeloperoxidase-ANCA. In the pulmonary function tests, forced expiratory volume in 1s (FEV1) was 28%. Thoracic computed tomography of the patient revealed central cystic bronchiectatic areas and mucus plugs (Figure...
The patient was diagnosed with ABPA and severe asthma, and treatment was started with oral methylprednisolone at 32 mg/day (0.5 mg/kg). The oral methylprednisolone dose was reduced to 16 mg on the 7th day of treatment and to 8 mg on the 14th day. On the 20th day of oral methylprednisolone treatment, mepolizumab was started at a dose of 100 mg/sc every four weeks due to an increase in respiratory complaints. The oral methylprednisolone dose was gradually reduced and stopped on the 60th day of treatment. After the mepolizumab treatment, improvements were observed in asthma control and pulmonary function tests at the 3rd, 6th, and 12th-month follow-up examinations. The number of asthma attacks requiring emergency department admission, eosinophil count, and total IgE values were decreased. (Table 1). Because the patient had limited respiratory functions and severe asthma, drug provocation tests with NSAIDs or aspirin desensitization could not be performed. The patient has been receiving mepolizumab treatment in our allergy clinic for one year and his asthmatic symptoms are under control.

**DISCUSSION**

The case presented here is of a patient with severe asthma concomitant with ABPA and N-ERD, who was successfully treated with mepolizumab. After the mepolizumab treatment, a decrease was observed in the patient’s respiratory symptoms (cough, dyspnea) and improvements in pulmonary function tests and asthma control. To the best of our knowledge, this report is the first case of severe asthma concomitant with ABPA and N-ERD to be treated with mepolizumab.

In the literature, there is a limited number of studies and case reports of treating an ABPA diagnosis with mepolizumab. In a study of 20 cases by Schleich et al. (5), it was observed that mepolizumab treatment led to a decreased oral corticosteroid dose and rate of exacerbation, and improved asthma control and quality of life in patients with ABPA. The authors stated that mepolizumab is an effective treatment for ABPA. In a case report by Altman MC et al. (6), the use of mepolizumab was reported to be an additional and effective treatment option for severe allergic disease.

| ACT  | 3rd month | 6th month | 12th month |
|------|-----------|-----------|------------|
| FEV1 (%) | 28 | 41 | 50 | 54 |
| Blood eosinophil count (cells/mcL) | 570 | 120 | 40 | 70 |
| Total IgE (kU/L) | 3976 | 3168 | 2040 | 1444 |

Table 1. ACT, FEV1, blood eosinophil, and total IgE values of the patient at baseline and at 3, 6, and 12 months post-mepolizumab treatment and the number of asthma attacks

| Number of asthma attacks* | Before mepolizumab treatment in one year | After mepolizumab treatment in one year |
|---------------------------|----------------------------------------|----------------------------------------|
| 4                         | [28, 50, 40, 70]                        | [20, 54, 50, 40]                       |

* Requiring emergency department admission and systemic steroid use for more than three days.
bronchopulmonary aspergillosis resistant to corticosteroids, antifungal therapy, and omalizumab. There are also case reports in the literature showing that mepolizumab is effective in the treatment of ABPA (1,7-11).

Mepolizumab is a monoclonal antibody developed against IL-5, and this cytokine releases eosinophils from the bone marrow and activates eosinophil functions (3). It has been shown that mepolizumab reduces the frequency of asthma exacerbations and the need for systemic corticosteroids in patients with severe eosinophilic asthma. The pre-treatment total IgE level does not affect the efficacy or side effects of mepolizumab treatment. Mepolizumab has been recommended as an effective treatment option in severe eosinophilic asthma with total IgE> 1500 IU/mL (12,13). In the current case, the patient had severe eosinophilic asthma and concomitant N-ERD. In patients with N-ERD, respiratory symptoms are caused by increased cysteinyl leukotriene levels as a result of dysregulation in arachidonic acid metabolism and increased eosinophilic inflammation of the airways. After the use of aspirin and other NSAIDs, there is an increase in leukotrienes in the airway as a result of the inhibition of the cyclooxygenase (COX) one enzyme, which causes respiratory symptoms. Patients with N-ERD have lower FEV\textsubscript{1} and a higher prevalence of CRSwNP (14).

The underlying pathogenetic mechanisms in patients with ABPA are complex. In patients with ABPA, the secretion of IL-4 and IL-5 from peripheral blood cells is increased, which contributes to the pathogenesis of ABPA by increasing TH2 (T Helper 2) inflammation (15). As patients with ABPA have high total IgE levels and specific antibodies to Aspergillus fumigatus, these patients may benefit from omalizumab therapy, and there are studies in the literature showing the efficacy of omalizumab treatment in patients with ABPA (16). In the current case, we administered mepolizumab because he had high levels of blood eosinophils but omalizumab was also a treatment option.

In conclusion, this case of severe asthma concomitant with ABPA and N-ERD was successfully treated with mepolizumab. Randomized double-blind placebo-controlled studies are needed to evaluate the efficacy of mepolizumab treatment in these patients.
9. Tsubouchi H, Tsuchida S, Yanagi S, Shigekusa T, Miura M, Sakaguchi K, et al. Successful treatment with mepolizumab in a case of allergic bronchopulmonary aspergillosis complicated with nontuberculous mycobacterial infection. Respir Med Case Rep 2019; 28: 100875. https://doi.org/10.1016/j.rmcr.2019.100875

10. Hirota S, Kobayashi Y, Ishiguro T, Nishida T, Kagiyama N, Shimizu Y, et al. Allergic bronchopulmonary aspergillosis successfully treated with mepolizumab: Case report and review of the literature. Respir Med Case Rep 2018; 26: 59-62. https://doi.org/10.1016/j.rmcr.2018.11.013

11. Terashima T, Shinozaki T, Iwami E, Nakajima T, Matsuzaki T. A case of allergic bronchopulmonary aspergillosis successfully treated with mepolizumab. BMC Pulm Med 2018; 18(1): 53. https://doi.org/10.1186/s12890-018-0617-5

12. Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. New Engl J Med 2014; 371: 1198-207. https://doi.org/10.1056/NEJMoa1403290

13. Menzella F, Galeone C, Bertolini F, Castagnetti C, Facciolongo N. Innovative treatments for severe refractory asthma: How to choose the right option for the right patient? J Asthma Allerg 2017; 10: 237. https://doi.org/10.2147/IAA.S144100

14. Woo SD, Luu QQ, Park HS. NSAID-Exacerbated Respiratory Disease (NERD): From pathogenesis to improved care. Front Pharmacol 2020; 11: 1147. https://doi.org/10.3389/fphar.2020.01147

15. Rathore VB, Johnson B, Fink JN, Kelly KJ, Greenberger PA, Kurup VP. T cell proliferation and cytokine secretion to T cell epitopes of asp f 2 in ABPA patients. Clin Immunol 2001; 100: 228-35. https://doi.org/10.1006/clim.2001.5056

16. Li JX, Fan LC, Li MH, Cao WJ, Xu JF. Beneficial effects of Omalizumab therapy in allergic bronchopulmonary aspergillosis: A synthesis review of published literature. Respir Med 2017; 122: 33-42. https://doi.org/10.1016/j.rmed.2016.11.019